...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Nonprofit Think Tank

someone very close to RVX and Zenith and who knows Don well says that he is now going through only the perfunctory appearance of making a serious value adding deal and is just trying to stretch out his salary and lifestyle. If they start laying people off, the game is over for RVX.

Share
New Message
Please login to post a reply